

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/34119 A2**(51) International Patent Classification<sup>7</sup>: A61K 9/14

(21) International Application Number: PCT/US00/31072


(22) International Filing Date:  
10 November 2000 (10.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/438,994 12 November 1999 (12.11.1999) US835C Country Club Drive, Libertyville, IL 60048 (US).  
SCHMITT, Eric, A.; 310 Evergreen Court, Libertyville,  
IL 60048 (US). QIU, Yihong; 6118 Honeysuckle Lane,  
Gurnee, IL 60031 (US).(74) Agents: SICKERT, Dugal, S. et al.; D377/AP6D, 100  
Abbott Park Road, Abbott Park, IL 60064-6050 (US).(81) Designated States (*national*): CA, JP, MX.(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).(71) Applicant: ABBOTT LABORATORIES [US/US];  
D377/AP6D, 100 Abbott Park Road, Abbott Park, IL  
60064-6050 (US).Published:  
— Without international search report and to be republished  
upon receipt of that report.(72) Inventors: KRILL, Steven, K.; 5133 Pembroke Court,  
Gurnee, IL 60031 (US). FORT, James, J.; 2700 Leafield  
Terrace, Midlothian, VA 23113 (US). LAW, Devalina;For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION



(57) Abstract: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

WO 01/34119 A2

## INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION

Technical Field of the Invention

5           The instant invention relates to the fields of  
pharmaceutical and organic chemistry, and provides novel solid  
dispersion pharmaceutical formulations which demonstrate an  
inhibition of crystallization.

10

Background of the Invention

One measure of the potential usefulness of an oral dosage  
form of a pharmaceutical agent is the bioavailability observed  
15 after oral administration of the dosage form. Various factors  
can affect the bioavailability of a drug when administered  
orally. These factors include aqueous solubility, drug  
absorption throughout the gastrointestinal tract, dosage  
strength, and first pass effect. Aqueous solubility is one of  
20 the most important of these factors. When a drug has poor  
aqueous solubility, attempts are often made to identify salts or  
other derivatives of the drug which have improved aqueous  
solubility. When a salt or other derivative of the drug is  
identified which has good aqueous solubility, it is generally

identified which has good aqueous solubility, it is generally accepted that an aqueous solution formulation of this salt or derivative will provide the optimum oral bioavailability. The bioavailability of the aqueous oral solution formulation of a drug is then generally used as the standard or ideal bioavailability against which other oral dosage forms are measured.

For a variety of reasons, including patient compliance and taste masking, a solid dosage form, such as a capsule or tablet, is usually preferred over a liquid dosage form. However, oral solid dosage forms of a drug generally provide a lower bioavailability than oral solutions of the drug. One goal of the development of a suitable solid dosage form is to obtain a bioavailability of the drug that is as close as possible to the ideal bioavailability demonstrated by the oral aqueous solution formulation of the drug.

An alternative dosage form is a solid dispersion. The term solid dispersion refers to the dispersion of one or more active ingredients in an inert carrier or matrix at solid state prepared by the melting (or fusion), solvent, or melting-solvent methods. (Chiou and Riegelman, *Journal of Pharmaceutical Sciences*, 60, 1281 (1971)). The dispersion of a drug or drugs in a solid diluent by

mechanical mixing is not included in this category. Solid dispersions may also be called solid-state dispersions.

Retroviral protease inhibiting compounds are useful for inhibiting HIV proteases *in vitro* and *in vivo*, and are  
5 useful for inhibiting HIV (human immunodeficiency virus) infections and for treating AIDS (acquired immunodeficiency syndrome). HIV protease inhibiting compounds typically are characterized by having poor oral bioavailability. Examples of HIV protease inhibiting compounds include  
10 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir);  
(2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl)  
15 amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378);  
N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl  
-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);  
20 N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);  
5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)-  
3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-  
t-butylamide;  
5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-  
5 amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-  
butylamide;  
[1S-[1R-(R-),2S\*]]-N<sup>1</sup> [3-[[[(1,1 -  
dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-  
hydroxy-1-(phenylmethyl)propyl]-2-[(2-  
10 quinolinylcarbonyl)amino]-butanediamide;  
VX-478; DMP-323; DMP-450; AG1343 (nelfinavir);  
BMS 186,318; SC-55389a; BILA 1096 BS; and U-140690, or  
combinations thereof.

While some drugs would be expected to have good  
15 solubility in organic solvents, it would not necessarily  
follow that oral administration of such a solution would  
give good bioavailability for the drug.

Polyethylene glycol (PEG) solid dispersion  
formulations are generally known to improve the dissolution  
20 and bioavailability of many compounds. However, Aungst et  
al. has recently demonstrated that this was unable to  
improve the bioavailability of an HIV protease inhibitor  
with a cyclic urea structural backbone, called DMP 323

(Aungst et al., *International Journal of Pharmaceutics*, 156, 79 (1997)).

In addition, some drugs tend to form crystals when placed in solution, which can be problematic during  
5 formulation.

Polyvinylpyrrolidone (PVP) is known to inhibit crystallization of drugs (Yohioka, M. et al., *J. Pharm. Sci.*, 84, 983, 1995). However, prior to the instant invention, the incorporation of PVP into a second polymer  
10 matrix, such as polyethylene glycol, has never been established.

U.S. 4,610,875 teaches a process for the preparation of a stable pharmaceutical dipyridamole composition containing PVP.

15 U.S. 4,769,236 teaches a process for the preparation of a stable pharmaceutical composition with a high dissolution rate in the gastrointestinal tract containing PVP, wherein the pharmaceutical agent is hydroflumethiazide, dipyridamole, hydrochlorothiazide,  
20 cyclothiazide, cyclopenthiazide, polythiazide, methyldopa, spironolactone, quinidine, cyanidol, metronidazole, ibuprofen, naproxen, erythromycin, glaphenin, furosemide, suloctidil, nitrofurantoin, indomethacin, flavoxate,

phenobarbital, cyclandelate, ketoprofen, natrihydrofuryl, or triamterene.

Thus, it would be a significant contribution to the art to provide a stable solid dispersion pharmaceutical  
5 formulation which demonstrates a lack of crystallization.

Summary of the Invention

The instant invention provides a stable solid dispersion pharmaceutical formulation comprising a pharmaceutical compound, a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone (PVP) or hydroxypropylmethylcellulose (HPMC).

Also provided by the instant invention is a pharmaceutical composition comprising a stable solid dispersion as described above with additional pharmaceutically acceptable carriers, diluents, or excipients.

Additionally provided by the instant invention is a method for preparing a stable solid dispersion as described above.

The instant invention still further provides methods of treatment comprising administering an effective amount of a stable solid dispersion as described above to a mammal in need of such treatment.



Brief Description of the Figures

Figure 1 illustrates the PXD patterns showing that Amorphous ABT-538 can be isolated within PEG alone.

5        Figure 2 illustrates the PXD patterns showing that Amorphous ABT-538 can be isolated with a PVP/PEG matrix.

Figure 3 illustrates the DSC thermograms of PEG, ABT-538, a physical mixture of the two and a solid dispersion. The absence of ABT-538 melting in the dispersion confirms  
10    the above PXD data showing amorphous ABT-538 present in the dispersion.

Figure 4 illustrates the DSC thermograms of PVP/PEG, ABT-538, a physical mixture of the two and a solid dispersion. The absence of ABT-538 melting in the  
15    dispersion confirms the above PXD data showing amorphous ABT-538 present in the dispersion.

Figure 5 illustrates the effect of PEG or PVP on the crystallization rate of amorphous ritonavir. The heat of fusion was used to calculate percent crystallized. In the  
20    presence of PVP the crystallization rate is slower.

Figure 6 illustrates the inhibition of crystallization using PVP.

Figure 7 illustrates PXD patterns of ABT-538 dispersions with and without PVP stored at 50°C. The data

demonstrate the improved physical stability of amorphous ABT-538 on storage.

Figure 8 illustrates PXD patterns of fenofibrate dispersions with and without PVP.

5        Figure 9 illustrates PXD patterns of fenofibrate dispersions with and without PVP and PEG.

Figure 10 illustrates PXD patterns of fenofibrate dispersions with and without PEG.

10       Figure 11 illustrates PXD patterns of fenofibrate dispersions with and without 10% PVP and PEG.

Figure 12 illustrates PXD patterns of griseofulvin dispersions with and without PEG.

Figure 13 illustrates PXD patterns of griseofulvin dispersions with and without PEG and PVP.

15       Figure 14 illustrates PXD patterns of griseofulvin dispersions with and without PEG.

Figure 15 illustrates PXD patterns of griseofulvin dispersions with and without PEG and PVP.

Detailed Description of the Invention

This invention pertains to the preparation of solid dispersion systems for pharmaceuticals which demonstrate a lack of crystallization.

The invention involves dispersion in a hydrophilic matrix of pharmaceuticals which exhibit poor aqueous solubility. The intent of such a formulation is to improve the aqueous dissolution properties and ultimately achieve improved bioavailability. Typically, the intent of such systems is to generate a dispersion of amorphous (high energy) drug within the matrix. The presence of the high energy drug form usually improves the dissolution rate. However, these systems are not often physically stable. The drug can crystallize over time, causing the loss of the desired properties and reduced shelf-life. The current invention enhances the physical stability of such formulations, thereby making this type of formulation more feasible.

In the instant invention, PEG 8000 is used as the hydrophilic matrix. Also employed in this formulation is polyvinylpyrrolidone (PVP), which is an example of a hydrophilic, amorphous polymer, and is used to inhibit crystallization. Other hydrophilic, amorphous polymers

include hydroxypropylmethylcellulose (HPMC), or other pharmaceutically acceptable hydrophilic, amorphous polymers. Specifically, PVP PF 17 is used within the PEG matrix to inhibit the crystallization of the drug of  
5 interest. A range of 1%-95% (w/w) of PVP can be employed, with a range of 1%-15% (w/w) being preferred.

The benefits of incorporating PVP into the PEG matrix are two fold. Firstly, processing PVP can be difficult due to its hygroscopicity. Secondly, when PVP dissolves a  
10 viscous layer at the solid-liquid interface forms. This viscous region can hinder dissolution of the drug. Another benefit of adding PVP is an increase in amorphous volume of the polymer matrix where drugs may reside. Since  
15 increase in amorphous volume could be important for fast dissolution. PVP has the added advantage of having a high  $T_g$ , which imparts stabilization of amorphous regions by reducing mobility. Therefore, this invention affords the benefits of the PEG properties in a dispersion along with  
20 those of PVP.

A solid (molecular) dispersion comprising an HIV protease inhibiting compound may be prepared by dissolving or dispersing the HIV protease inhibiting compound in a sufficient amount of an organic solvent followed by

dispersion into a suitable water soluble carrier. Suitable organic solvents include pharmaceutically acceptable solvents such as methanol, ethanol, or other organic solvents in which the protease inhibitor is soluble.

- 5 Suitable water soluble carriers include polymers such as polyethylene glycol (PEG), pluronics, pentaerythritol, pentaerythritol tetraacetate, polyoxyethylene stearates, poly-ε-caprolactone, and the like.

The organic solvent (preferably ethanol) may then be  
10 evaporated away, leaving the drug dispersed/dissolved in the molten matrix, which is then cooled. The solid matrix has the compound finely dispersed (molecular dispersion) in such a way that dissolution of the drug is maximized, thus improving the bioavailability of a drug exhibiting  
15 dissolution rate limited absorption. Ease of manufacturing is also an attribute to this type of formulation. Once the organic solvent is evaporated to yield a solid mass, the mass may be ground, sized, and optionally formulated into an appropriate delivery system. Thus, by improving the  
20 dissolution of a poorly water soluble drug, the drug in a suitable carrier may be filled into a gelatin capsule as a solid, or the matrix may potentially be compressed into a tablet.

The delivery system of the present invention results in increased solubility and bioavailability, and improved dissolution rate of the HIV protease inhibiting compound.


Other pharmaceutically-acceptable excipients may be  
5 added to the formulation prior to forming the desired final product. Suitable excipients include lactose, starch, magnesium stearate, or other pharmaceutically-acceptable fillers, diluents, lubricants, disintegrants, and the like, that might be needed to prepare a capsule  
10 or tablet.

The resulting composition comprising the pharmaceutical compound may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into capsules, or made into  
15 tablets for oral administration, or delivered by some other means obvious to those skilled in the art. The composition can be used to improve the oral bioavailability and solubility of said HIV protease inhibiting compound.

20 Total daily dosing of the pharmaceutical compound may be administered to a human in single or divided doses in amounts, for example, from 0.001 to 1000 mg/kg body weight daily, but more usually 0.1 to 50 mg/kg body weight daily. Dosage unit compositions may contain such amounts of

submultiples thereof to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, 5 time of administration, rate of excretion, drugs administered in combination and the severity of the particular disease undergoing therapy.

One type of pharmaceutical compound that may be employed in the practice of the present invention is an HIV 10 protease inhibitor. An example of an HIV protease inhibitor is ABT-538 (ritonavir), the chemical structure of which is represented hereinbelow as a compound of formula I




15

A compound of formula I is an HIV protease inhibitor marketed by Abbott Laboratories under the tradename Norvir<sup>®</sup>, with the common name ritonavir [(2S,3S,5S)-5-(N-(N-(N-

methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-  
L-valinyl)amino-2-(N-  
((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-  
hydroxyhexane]. This and other compounds as well as  
5 methods for preparing same are disclosed in U.S. Patent  
Nos. 5,648,497 and 5,541,206, the disclosures of which  
are herein incorporated by reference.

Additional HIV protease inhibitors which may be  
formulated into a solid dispersion of the instant  
10 invention include compounds of formula II



II



A compound of formula II is known as ABT-378  
((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-  
hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-  
butanoyl)amino-1,6-diphenylhexane). This and other  
5 compounds, as well as methods for preparing same, are  
identified in U.S. Patent No. 5,914,332, the disclosure  
of which is herein incorporated by reference.

10

Other types of pharmaceutical compounds which may be  
employed in the practice of the present invention include  
but are not limited to antibacterial agents, antifungal  
15 agents such as griseofulvin, chemotherapeutic agents,  
agents for treating hyperlipidemia such as fenofibrate,  
and the like.

20 The following Examples are provided to further  
illustrate the present invention.

**EXAMPLES****Equipment:**

5

**DSC**

DSC measurements were made using a Mettler DSC 30 unit. Samples (4-7mg) were sealed in standard 40  $\mu$ l aluminum crucibles with a single hole punched in the  
10 lids. An empty crucible of the same type was used as a reference.

**X-ray Powder Diffraction Analysis**

An X-ray powder diffraction (XPD) pattern was  
15 obtained with a Scintag<sup>®</sup> XDS 2000  $\theta/\theta$  diffraction system equipped with a 2 kW normal focus X-ray tube and a liquid nitrogen cooled germanium solid state detector.

**Isothermal Calorimetry (TAM)**

20 The recrystallization reactions of 30% ABT-538 in PEG or PEG:PVP (95:5) solid dispersions were monitored via isothermal calorimetry (Thermometric 2277 Calorimeter) at 40 °C. Since crystallization is an exothermic process, a positive power output indicates

crystallization. The magnitude of the power output at any time is proportional to the rate of crystallization. XPD was used to confirm crystallization.

5   **HPLC**

The potency values of all the dispersions as well as the dissolution sample concentrations were determined via HPLC.

10       The effect of PVP on the crystallization rate of the drug in each dispersion system (drug with polymer) was investigated with the appropriate experimental technique. The results of these studies are provided in Figures 1-15.

15

Three pharmaceuticals of different properties were employed to demonstrate the general applicability of the instant invention. These compounds are identified in Table 1 below:

Table 1  
Model Compounds

| Property/Compound   | ABT-538 | Fenofibrate | Griseofulvin |
|---------------------|---------|-------------|--------------|
| MW (g/mole)         | 720.96  | 360.84      | 352.77       |
| T <sub>m</sub> (°C) | 124     | 79          | 218.13       |
| T <sub>g</sub> (°C) | 45.8    | -21.7       | 91           |

Example 1

Dispersion Preparations

**A. Ritonavir (ABT-538) Dispersion Preparation:**

The samples were prepared by dissolving ABT-538 in a small volume of 200 proof ethanol in a 250 ml round bottom flask. The flask was vortexed and then placed in a water bath maintained at 75 °C. The PEG 8000 was added to the hot alcohol solution with continual swirling until the PEG melted. The flask was then attached to a rotary evaporator, immersed in the water bath (75 °C) under vacuum for 15 minutes to remove the ethanol. After the majority of ethanol had evaporated, the flask was immersed in an ice

bath for 15 minutes. The contents of the flask were then vacuum dried at room temperature overnight to remove residual alcohol. The dispersion was removed from the flask, gently ground, and sized to 40-100 mesh size. The drug loads used for these dispersions were 10, 20 and 30% w/w.

**B. ABT-378 Dispersion Preparation:**

The solid dispersion of 30% ABT-538 in 95:5 PEG8000:PVP was prepared by dissolving the ABT-538 and PVP 17 PF in a small volume of 200 proof ethanol in a 250 ml round bottom flask. The remainder of the process was as described above. A 30% ABT-538 dispersion in 85:15 PEG8000:PVP was also prepared similarly as were dispersions of 10 or 20% PVP 17PF in PEG 8000 without drug.

**C. Fenofibrate Dispersion Preparation:**

**20 15% Fenofibrate in PEG 8000:**

Both fenofibrate and PEG 8000 were sized to 40-100 mesh prior to mixing with a spatula on weighing paper. The mixture was then added to a 25 ml beaker and heated to 85°C in a water bath until the all the material had

melted. The molten solution was then poured onto a chilled X-ray sample holder to rapidly solidify the solution. The solid sample was immediately used to monitor the crystallization rate via X-ray powder  
5 diffraction.

**15% Fenofibrate in 90:10 PEG 8000:PVP:**

Fenofibrate (40-100 mesh) was added to the 90:10 PEG 8000:PVP control dispersion (see above) which was also  
10 sized to 40-100 mesh and mixed with spatula on a piece of weighing paper. The mixture was then processed as described above for the 15% fenofibrate dispersion in PEG 8000.

**15 D. Griseofulvin Dispersion Preparation:**

**15% griseofulvin in PEG 8000:**

Both griseofulvin and PEG 8000 were sized to 40-100  
20 mesh prior to mixing on a weighing paper with a spatula. The sample was then added to an 4 ml stainless steel vessel which was sealed under a N<sub>2</sub> atmosphere. The vessel was then immersed into an oil bath maintained at 180°C. The sample was occasionally shaken to mix the molten  
25 contents. After 5 minutes the vessel was immersed into a

liquid N<sub>2</sub> bath for 30 minutes. The contents of the vessel were removed, gently ground and sized to 40-100 mesh.

**15% griseofulvin in 80:20 PEG 8000:PVP:**

5

This dispersion was prepared in a similar manner as describe above for the 15% griseofulvin in PEG 8000 dispersion using the 80:20 PEG8000:PVP control dispersion.

10

**E. Results:**

**ABT-538:**

Figure 1 shows the X-ray powder diffraction (XPD) pattern of ABT-538, processed PEG 8000, a physical  
15 mixture of the two components and the 30% solid dispersion. A similar plot is shown in Figure 2 with PVP incorporated into the matrix. It is apparent from these figures that ABT-538 is not crystalline within either matrix. Figure 3 shows the DSC thermograms of ABT-538,  
20 PEG8000, the 30% physical mixture and the dispersion. A similar plot is seen in Figure 4 for the PEG:PVP dispersion. The endotherm associated with drug melting can clearly be discerned from the other components. Thus, it is possible to follow the kinetics of ABT-538

crystallization via DSC measurements. Crystallization kinetics were determined by heating the samples to 85°C, holding them isothermally for predetermined times followed by heating through the melting transition temperature of ABT-538. The heats of fusion were determined and ratioed against the heat of fusion of the drug melting in the physical mixture, giving the fraction crystallized. The percent crystallized as a function of isothermal (85°C) hold time is shown in Figure 5. It is clear from this experiment that the presence of PVP within the matrix suppresses the crystallization rate of ABT-538.

The crystallization rate was also followed via the heat associated with crystallization of ABT-538 using a isothermal calorimetry. The shapes and magnitudes of the crystallization peaks in Figure 6 indicate that ABT-538 crystallizes more readily in the PEG matrix as compared to the PEG:PVP matrix. This stabilizing effect of PVP is also reflected in the times required for complete crystallization (time to reach baseline) which were <10 hours for PEG and >30 hours for PEG:PVP (95:5). These data support the previous DSC results.

An additional study was performed with a dispersion containing 15% PVP. The samples were held at 50°C (above



the  $T_g$  of ABT-538) and X-ray diffraction patterns were measured over time to monitor for the appearance of crystalline ABT-538. Figure 7 shows that in the presence of PVP, crystalline ABT-538 is not present after 5 272 hours, while in PEG8000 alone crystalline drug is detected at 233 hours (and before, data not shown).

**Fenofibrate:**

Figure 8 shows the XPD patterns of PEG 8000, 10 fenofibrate, a 15% physical mixture and the 15% fenofibrate solid dispersion. The figure illustrates that the fenofibrate is X-ray-amorphous within the matrix. A similar plot with the XPD patterns for the 15% fenofibrate dispersion in a 90:10 PEG 8000:PVP matrix is 15 presented in Figure 9. Again, the fenofibrate is amorphous. Upon storage at 25°C, the fenofibrate begins to crystallize in the PEG 8000 matrix within 1 hour (Figure 10). Additional crystallization follows upto 12 hours, when the experiment was terminated. In the 20 presence of PVP (Figure 11), the fenofibrate does not crystallize in the timeframe of the experiment. This clearly demonstrates the inhibitory effects of PVP on crystallization within the PEG 8000 matrix.

**Griseofulvin:**

Similar XPD patterns for the griseofulvin dispersion in PEG 8000 and 80:20 PEG 8000:PVP matrices are shown in Figures 12 and 13, respectively. In both instances, amorphous griseofulvin is isolated within the respective matrices. The XPD rate of crystallization experiments show that after one hour at 25°C, griseofulvin begins to crystallize (Figure 14). However, in the presence of PVP (Figure 15), crystallization is not observed even after 15 hours under the same conditions. This again demonstrates the inhibitory effects of PVP amorphous drug crystallization within a PEG matrix.

**15 E. Conclusions:**

The data presented demonstrate that PVP incorporated within a hydrophilic matrix, such as PEG 8000, inhibits crystallization of drug molecules having varying physicochemical properties. Thus, the instant invention has a broad application to development of viable solid dispersion formulations where the high energy amorphous (non-crystalline) form of a drug is desired.

Example 2Stability of Dispersion in Molten PEG 8000

The stability of the dispersion of ABT-538 in PEG  
5 8000 in the molten state at 70 °C was examined.  
Individual approximately 5 mg quantities of the  
dispersion (aged for 6 weeks at room temperature) were  
placed in 4 ml glass vials. These vials, with the  
exception of the initial time point, were placed in a  
10 70 °C oven which was sampled at pre-determined intervals,  
chilled in ice water and placed in the freezer until HPLC  
analysis. After all samples were collected, they were  
analyzed for ABT-538 content by HPLC. The HPLC system  
consisted of a Hitachi AS 4000 autosampler, SP 8800  
15 ternary pump, Applied Biosystems 783 detector, and PE  
Nelson Data acquisition system. Other chromatographic  
details included a Regis Little Champ 5 cm C-18 column, a  
mobile phase consisting of an aqueous solution of 0.1%  
trifluoroacetic acid in 10 mM aqueous tetramethyl  
20 ammonium perchlorate (TMAP)/acetonitrile/methanol  
(55/40/5). The flow rate was 1 ml/minute, the wavelength  
of detection was 205 nm, and the injection volume was 100  
μl. Standard curves of peak area of ABT-538 vs.

concentration in the range of interest were compared with experimentally obtained area counts.

5

Example 3Protocol For Oral Bioavailability Studies

Dogs (beagle dogs, mixed sexes, weighing 7-14 kg) are  
10 fasted overnight prior to dosing, but are permitted water  
*ad libitum*. Each dog receives a 100 µg/kg subcutaneous  
dose of histamine approximately 30 minutes prior to dosing.  
Each dog receives a single solid dosage form corresponding  
to a 5 mg/kg dose of the drug. The dose is followed by  
15 approximately 10 milliliters of water. Blood samples are  
obtained from each animal prior to dosing and at 0.25, 0.5,  
1.0, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug  
administration. The plasma is separated from the red cells  
by centrifugation and frozen (- 30 °C) until analysis. The  
20 concentrations of parent drug is determined by reverse  
phase HPLC with low wavelength UV detection following  
liquid-liquid extraction of the plasma samples. The parent  
drug area under the curve is calculated by the trapezoidal  
method over the time course of the study. The absolute  
25 bioavailability of each test composition is calculated by  
comparing the area under the curve after oral dosing to

that obtained from a single intravenous dose. Each capsule or capsule composition is evaluated in a group containing at least six dogs. The values reported are averages for each group of dogs.

## WE CLAIM:

1. A pharmaceutical composition comprising a solid dispersion of a pharmaceutical compound, a water soluble  
5 carrier, and a crystallization inhibitor selected from the group consisting of polyvinylpyrrolidone (PVP) and hydroxypropylcellulose (HPMC).

2. The composition of Claim 1 wherein said water  
10 soluble carrier is polyethylene glycol (PEG).

3. The composition of Claim 1 wherein said pharmaceutical compound is an HIV protease inhibitor dissolved in an organic solvent.

15

4. The composition of Claim 3 wherein said organic solvent is ethanol.

5. The composition of Claim 3 wherein said HIV  
20 protease inhibitor is 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir).

6. The composition of Claim 3 wherein said HIV  
protease inhibitor is (2S, 3S, 5S)-2-(2,6-  
Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-  
pyrimid-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane  
5 (ABT-378).

7. The composition of Claim 3 wherein said HIV  
protease inhibitor is a combination of 2S,3S,5S)-5-(N-(N-  
((N-methyl-N-((2-isopropyl-4-  
10 thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-  
thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-  
hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-  
Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-  
pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane  
15 (ABT-378).

8. The composition of Claim 2 wherein said solid  
dispersion is encapsulated in a hard gelatin capsule.

20 9. The composition of Claim 2 wherein said solid  
dispersion is compressed into a tablet.

10. The composition of Claim 1 further comprising an  
additive or a mixture of additives independently selected

from the group consisting of pharmaceutically acceptable surfactants and antioxidants.

11. The composition of Claim 1 wherein said  
5 pharmaceutical compound is fenofibrate.

12. The composition of Claim 1 wherein said  
pharmaceutical compound is griseofulvin.

10 13. A method of preparing a composition of Claim 1  
which comprises:

- a) dissolving a pharmaceutical compound inhibitor  
into an organic solvent to form a solution;
- b) adding a water soluble carrier to said  
15 solution to form a mixture;
- c) adding PVP to said mixture of step b);
- d) optionally flash evaporating said solvent;
- e) optionally drying the resulting residue  
remaining after evaporation;
- 20 f) optionally grinding and sieving the solid  
dispersion to obtain a resultant product.



14. The method of Claim 13 additionally comprising encapsulating the solid dispersion in a hard gelatin capsule.

5 15. The method of Claim 13 additionally comprising compressing said solid dispersion into a tablet.

16. The method of Claim 13 wherein said pharmaceutical compound is an HIV protease inhibitor.

10

17. The method of Claim 16 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-15 thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6)-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]amino-1,6-diphenylhexane (ABT-378).

20

18. The method of Claim 13 wherein said solvent is ethanol.

19. The method of Claim 13 wherein said water soluble carrier is polyethylene glycol (PEG).

20. A method of treating an HIV infection comprising  
5 administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is an HIV protease inhibitor.

21. The method of Claim 20 wherein said HIV protease  
10 inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6)-  
15 Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]amino-1,6-diphenylhexane (ABT-378).

22. A method of treating hyperlipidemia comprising  
20 administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is fenofibrate.

23. A method of treating a fungal infection .  
comprising administering an effective amount of a solid  
dispersion of Claim 1 to a mammal in need of such  
treatment, wherein said pharmaceutical compound is  
5 griseofulvin.




Figure 1




Figure 2




Figure 3




Figure 4

**Missing at the time of publication**

**Figure 5**



ABT-538 Isothermal Calorimetry (40°C)

**Missing at the time of publication**

**Figure 6**




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13






Figure 14




Figure 15

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/34119 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 9/14,**  
**A61P 31/18**

835C Country Club Drive, Libertyville, IL 60048 (US).  
**SCHMITT, Eric, A.**; 310 Evergreen Court, Libertyville,  
IL 60048 (US). **QIU, Yihong**; 6118 Honeysuckle Lane,  
Gurnee, IL 60031 (US).

(21) International Application Number: PCT/US00/31072

(22) International Filing Date:  
10 November 2000 (10.11.2000)

(74) Agents: **SICKERT, Dugal, S. et al.**; D377/AP6D, 100  
Abbott Park Road, Abbott Park, IL 60064-6050 (US).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, MX.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).

(30) Priority Data:  
09/438,994 12 November 1999 (12.11.1999) US

Published:  
— with international search report


(71) Applicant: **ABBOTT LABORATORIES [US/US];**  
D377/AP6D, 100 Abbott Park Road, Abbott Park, IL  
60064-6050 (US).

(88) Date of publication of the international search report:  
22 November 2001

(72) Inventors: **KRILL, Steven, K.**; 5133 Pembroke Court,  
Gurnee, IL 60031 (US). **FORT, James, J.**; 2700 Leaffield  
Terrace, Midlothian, VA 23113 (US). **LAW, Devalina;**

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION



(57) Abstract: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

WO 01/34119 A3

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/31072

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K9/14 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | B.J. AUNGST ET AL.: "Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses"<br>INTERNATIONAL JOURNAL OF PHARMACEUTICS,<br>vol. 156, no. 1, 1997, pages 79-88,<br>XP001009732<br>Amsterdam (NL)<br>cited in the application<br>page 81, paragraph 2.2<br>page 84; table 2 | 1-4.8,20              |
| A          | ---   | 13                    |
| X          | US 4 769 236 A (PANOS ET AL.)<br>6 September 1988 (1988-09-06)<br>cited in the application<br>claim 1   | 1,2,4                 |
|            | ---   |                       |
|            | -/--  |                       |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

19 June 2001

Date of mailing of the international search report

05/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

# INTERNATIONAL SEARCH REPORT

Intern      1al Application No  
PCT/US 00/31072

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.     |
|------------|---|---------------------------|
| X          | WO 90 06115 A (HENNING BERLIN GMBH CHEMIE-<br>UND PHARMAWERK) 14 June 1990 (1990-06-14)<br><br>page 3, line 3 -page 6, line 7<br>page 8; example 1<br>----- | 1,2,4,<br>13-15,<br>18,19 |
| X          | GB 2 053 681 A (YAMANOUCHI PHARMACEUTICAL<br>CO. LTD.) 11 February 1981 (1981-02-11)<br>page 3; example 3<br>-----  | 1,2                       |
| X          | WO 96 23499 A (SHERMAN)<br>8 August 1996 (1996-08-08)<br>page 10; example 1<br>-----  | 1,2                       |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/31072

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| US 4769236 A                              | 06-09-1988          | FR 2525108 A               | 21-10-1983          |
|   |                     | AR 230183 A                | 01-03-1984          |
|   |                     | AT 389813 B                | 12-02-1990          |
|   |                     | AT 427282 A                | 15-07-1989          |
|   |                     | AU 555579 B                | 02-10-1986          |
|   |                     | AU 9043182 A               | 27-10-1983          |
|   |                     | BE 894942 A                | 09-05-1983          |
|   |                     | CA 1225029 A               | 04-08-1987          |
|   |                     | CH 655003 A                | 27-03-1986          |
|   |                     | DE 3241097 A               | 20-10-1983          |
|   |                     | ES 517444 D                | 16-05-1985          |
|   |                     | ES 8505249 A               | 01-09-1985          |
|   |                     | GB 2119784 A,B             | 23-11-1983          |
|   |                     | IE 54084 B                 | 07-06-1989          |
|   |                     | IT 1153099 B               | 14-01-1987          |
|   |                     | JP 1677967 C               | 13-07-1992          |
|   |                     | JP 3041444 B               | 24-06-1991          |
|   |                     | JP 58183615 A              | 26-10-1983          |
|   |                     | LU 84468 A                 | 13-06-1983          |
|   |                     | NL 8204461 A               | 16-11-1983          |
|   |                     | PT 75867 A,B               | 01-12-1982          |
|   |                     | SE 8206697 A               | 20-10-1983          |
|   |                     | US 4610875 A               | 09-09-1986          |
| WO 9006115 A                              | 14-06-1990          | DE 3839825 A               | 13-06-1990          |
|   |                     | AT 92321 T                 | 15-08-1993          |
|   |                     | DE 58905187 D              | 09-09-1993          |
|   |                     | EP 0445158 A               | 11-09-1991          |
|   |                     | ES 2058602 T               | 01-11-1994          |
|   |                     | JP 2965689 B               | 18-10-1999          |
|   |                     | JP 4502004 T               | 09-04-1992          |
|   |                     | US 5368864 A               | 29-11-1994          |
| GB 2053681 A                              | 11-02-1981          | JP 1272484 C               | 11-07-1985          |
|   |                     | JP 56133217 A              | 19-10-1981          |
|   |                     | JP 59048810 B              | 29-11-1984          |
|   |                     | JP 1591530 C               | 30-11-1990          |
|   |                     | JP 2009007 B               | 28-02-1990          |
|   |                     | JP 56049314 A              | 02-05-1981          |
|   |                     | CA 1146866 A               | 24-05-1983          |
|   |                     | CH 648484 A                | 29-03-1985          |
|   |                     | DE 3024858 A               | 22-01-1981          |
|   |                     | ES 493152 D                | 16-11-1981          |
|   |                     | ES 8200557 A               | 01-02-1982          |
|   |                     | ES 499854 D                | 01-06-1982          |
|   |                     | ES 8205125 A               | 16-09-1982          |
|   |                     | FR 2460667 A               | 30-01-1981          |
|   |                     | FR 2489146 A               | 05-03-1982          |
|   |                     | IT 1132169 B               | 25-06-1986          |
|   |                     | SE 448342 B                | 16-02-1987          |
|   |                     | SE 8004938 A               | 06-01-1981          |
|   |                     | US 4343789 A               | 10-08-1982          |
|   |                     | US 4404183 A               | 13-09-1983          |
|   |                     | US 4673564 A               | 16-06-1987          |
| WO 9623499 A                              | 08-08-1996          | NZ 270439 A                | 26-04-1996          |
|   |                     | AU 706699 B                | 24-06-1999          |
|   |                     | AU 4478496 A               | 21-08-1996          |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/31072

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9623499 A                              |                     | CA 2212309 A               | 08-08-1996          |
|   |                     | EP 0809497 A               | 03-12-1997          |
|   |                     | US 6132772 A               | 17-10-2000          |
|   |                     | ZA 9600576 A               | 14-08-1996          |
| <hr/>                                     |                     |                            |                     |





CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/034119 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 9/14**,  
A61P 31/18

835C Country Club Drive, Libertyville, IL 60048 (US).  
**SCHMITT, Eric, A.**; 310 Evergreen Court, Libertyville,  
IL 60048 (US). **QIU, Yihong**; 6118 Honeysuckle Lane,  
Gurnee, IL 60031 (US).

(21) International Application Number: PCT/US00/31072

(22) International Filing Date:  
10 November 2000 (10.11.2000)

(74) Agents: **SICKERT, Dugal, S. et al.**; D377/AP6D, 100  
Abbott Park Road, Abbott Park, IL 60064-6050 (US).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, MX.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).

(30) Priority Data:  
09/438,994 12 November 1999 (12.11.1999) US

Published:  
— with international search report

(71) Applicant: **ABBOTT LABORATORIES** [US/US];  
D377/AP6D, 100 Abbott Park Road, Abbott Park, IL  
60064-6050 (US).


(88) Date of publication of the international search report:  
22 November 2001

(72) Inventors: **KRILL, Steven, K.**; 5133 Pembroke Court,  
Gurnee, IL 60031 (US). **FORT, James, J.**; 2700 Leaffield  
Terrace, Midlothian, VA 23113 (US). **LAW, Devalina**;

(48) Date of publication of this corrected version:  
26 September 2002

[Continued on next page]

(54) Title: INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION



(57) Abstract: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

WO 01/034119 A3



**(15) Information about Correction:**

see PCT Gazette No. 39/2002 of 26 September 2002, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION

Technical Field of the Invention

5       The instant invention relates to the fields of pharmaceutical and organic chemistry, and provides novel solid dispersion pharmaceutical formulations which demonstrate an inhibition of crystallization.

10

Background of the Invention

One measure of the potential usefulness of an oral dosage form of a pharmaceutical agent is the bioavailability observed after oral administration of the dosage form. Various factors can affect the bioavailability of a drug when administered orally. These factors include aqueous solubility, drug absorption throughout the gastrointestinal tract, dosage strength, and first pass effect. Aqueous solubility is one of the most important of these factors. When a drug has poor aqueous solubility, attempts are often made to identify salts or other derivatives of the drug which have improved aqueous solubility. When a salt or other derivative of the drug is identified which has good aqueous solubility, it is generally

identified which has good aqueous solubility, it is generally accepted that an aqueous solution formulation of this salt or derivative will provide the optimum oral bioavailability. The bioavailability of the aqueous oral solution formulation of a drug is then generally used as the standard or ideal bioavailability against which other oral dosage forms are measured.

For a variety of reasons, including patient compliance and taste masking, a solid dosage form, such as a capsule or tablet, is usually preferred over a liquid dosage form. However, oral solid dosage forms of a drug generally provide a lower bioavailability than oral solutions of the drug. One goal of the development of a suitable solid dosage form is to obtain a bioavailability of the drug that is as close as possible to the ideal bioavailability demonstrated by the oral aqueous solution formulation of the drug.

An alternative dosage form is a solid dispersion. The term solid dispersion refers to the dispersion of one or more active ingredients in an inert carrier or matrix at solid state prepared by the melting (or fusion), solvent, or melting-solvent methods. (Chiou and Riegelman, *Journal of Pharmaceutical Sciences*, 60, 1281 (1971)). The dispersion of a drug or drugs in a solid diluent by

mechanical mixing is not included in this category. Solid dispersions may also be called solid-state dispersions.

Retroviral protease inhibiting compounds are useful for inhibiting HIV proteases *in vitro* and *in vivo*, and are  
 5 useful for inhibiting HIV (human immunodeficiency virus) infections and for treating AIDS (acquired immunodeficiency syndrome). HIV protease inhibiting compounds typically are characterized by having poor oral bioavailability.

Examples of HIV protease inhibiting compounds include

- 10 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir);
- (2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl)
- 15 amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378);
- N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);
- 20 N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);
- 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)-  
3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-  
t-butylamide;  
5 -isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-  
amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-  
butylamide;  
[1S-[1R-(R-),2S\*]]-N<sup>1</sup> [3-[[[(1,1 -  
dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-  
hydroxy-1-(phenylmethyl)propyl]-2-[(2-  
10 quinolinylylcarbonyl)amino]-butanediamide;  
VX-478; DMP-323; DMP-450; AG1343(nelfinavir);  
BMS 186,318; SC-55389a; BILA 1096 BS; and U-140690, or  
combinations thereof.

While some drugs would be expected to have good  
15 solubility in organic solvents, it would not necessarily  
follow that oral administration of such a solution would  
give good bioavailability for the drug.

Polyethylene glycol (PEG) solid dispersion  
formulations are generally known to improve the dissolution  
20 and bioavailability of many compounds. However, Aungst et  
al. has recently demonstrated that this was unable to  
improve the bioavailability of an HIV protease inhibitor  
with a cyclic urea structural backbone, called DMP 323

(Aungst et al., *International Journal of Pharmaceutics*, 156, 79 (1997)).

In addition, some drugs tend to form crystals when placed in solution, which can be problematic during  
5 formulation.

Polyvinylpyrrolidone (PVP) is known to inhibit crystallization of drugs (Yohioka, M. et al., *J. Pharm. Sci.*, 84, 983, 1995). However, prior to the instant invention, the incorporation of PVP into a second polymer  
10 matrix, such as polyethylene glycol, has never been established.

U.S. 4,610,875 teaches a process for the preparation of a stable pharmaceutical dipyridamole composition containing PVP.

15 U.S. 4,769,236 teaches a process for the preparation of a stable pharmaceutical composition with a high dissolution rate in the gastrointestinal tract containing PVP, wherein the pharmaceutical agent is hydroflumethiazide, dipyridamole, hydrochlorothiazide,  
20 cyclothiazide, cyclopenthiazide, polythiazide, methyldopa, spironolactone, quinidine, cyanidol, metronidazole, ibuprofen, naproxen, erythromycin, glaphenin, furosemide, suloctidil, nitrofurantoin, indomethacin, flavoxate,

phenobarbital, cyclandelate, ketoprofen, natrihydrofuryl, or triamterene.

Thus, it would be a significant contribution to the art to provide a stable solid dispersion pharmaceutical  
5 formulation which demonstrates a lack of crystallization.



Summary of the Invention

The instant invention provides a stable solid dispersion pharmaceutical formulation comprising a  
5 pharmaceutical compound, a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone (PVP) or hydroxypropylmethylcellulose (HPMC).

Also provided by the instant invention is a  
10 pharmaceutical composition comprising a stable solid dispersion as described above with additional pharmaceutically acceptable carriers, diluents, or excipients.

Additionally provided by the instant invention is a  
15 method for preparing a stable solid dispersion as described above.

The instant invention still further provides methods of treatment comprising administering an effective amount of a stable solid dispersion as described above to a mammal  
20 in need of such treatment.

Brief Description of the Figures

Figure 1 illustrates the PXD patterns showing that Amorphous ABT-538 can be isolated within PEG alone.

5        Figure 2 illustrates the PXD patterns showing that Amorphous ABT-538 can be isolated with a PVP/PEG matrix.

Figure 3 illustrates the DSC thermograms of PEG, ABT-538, a physical mixture of the two and a solid dispersion. The absence of ABT-538 melting in the dispersion confirms  
10        the above PXD data showing amorphous ABT-538 present in the dispersion.

Figure 4 illustrates the DSC thermograms of PVP/PEG, ABT-538, a physical mixture of the two and a solid dispersion. The absence of ABT-538 melting in the  
15        dispersion confirms the above PXD data showing amorphous ABT-538 present in the dispersion.

Figure 5 illustrates the effect of PEG or PVP on the crystallization rate of amorphous ritonavir. The heat of fusion was used to calculate percent crystallized. In the  
20        presence of PVP the crystallization rate is slower.

Figure 6 illustrates the inhibition of crystallization using PVP.

Figure 7 illustrates PXD patterns of ABT-538 dispersions with and without PVP stored at 50°C. The data

demonstrate the improved physical stability of amorphous ABT-538 on storage.

Figure 8 illustrates PXD patterns of fenofibrate dispersions with and without PVP.

5        Figure 9 illustrates PXD patterns of fenofibrate dispersions with and without PVP and PEG.

Figure 10 illustrates PXD patterns of fenofibrate dispersions with and without PEG.

10       Figure 11 illustrates PXD patterns of fenofibrate dispersions with and without 10% PVP and PEG.

Figure 12 illustrates PXD patterns of griseofulvin dispersions with and without PEG.

Figure 13 illustrates PXD patterns of griseofulvin dispersions with and without PEG and PVP.

15       Figure 14 illustrates PXD patterns of griseofulvin dispersions with and without PEG.

Figure 15 illustrates PXD patterns of griseofulvin dispersions with and without PEG and PVP.

Detailed Description of the Invention

This invention pertains to the preparation of solid dispersion systems for pharmaceuticals which demonstrate a lack of crystallization.

The invention involves dispersion in a hydrophilic matrix of pharmaceuticals which exhibit poor aqueous solubility. The intent of such a formulation is to improve the aqueous dissolution properties and ultimately achieve improved bioavailability. Typically, the intent of such systems is to generate a dispersion of amorphous (high energy) drug within the matrix. The presence of the high energy drug form usually improves the dissolution rate. However, these systems are not often physically stable. The drug can crystallize over time, causing the loss of the desired properties and reduced shelf-life. The current invention enhances the physical stability of such formulations, thereby making this type of formulation more feasible.

In the instant invention, PEG 8000 is used as the hydrophilic matrix. Also employed in this formulation is polyvinylpyrrolidone (PVP), which is an example of a hydrophilic, amorphous polymer, and is used to inhibit crystallization. Other hydrophilic, amorphous polymers

include hydroxypropylmethylcellulose (HPMC), or other pharmaceutically acceptable hydrophilic, amorphous polymers. Specifically, PVP PF 17 is used within the PEG matrix to inhibit the crystallization of the drug of  
5 interest. A range of 1%-95% (w/w) of PVP can be employed, with a range of 1%-15% (w/w) being preferred.

The benefits of incorporating PVP into the PEG matrix are two fold. Firstly, processing PVP can be difficult due to its hygroscopicity. Secondly, when PVP dissolves a  
10 viscous layer at the solid-liquid interface forms. This viscous region can hinder dissolution of the drug. Another benefit of adding PVP is an increase in amorphous volume of the polymer matrix where drugs may reside. Since polyethylene glycols tend to be highly crystalline, this  
15 increase in amorphous volume could be important for fast dissolution. PVP has the added advantage of having a high  $T_g$ , which imparts stabilization of amorphous regions by reducing mobility. Therefore, this invention affords the benefits of the PEG properties in a dispersion along with  
20 those of PVP.

A solid (molecular) dispersion comprising an HIV protease inhibiting compound may be prepared by dissolving or dispersing the HIV protease inhibiting compound in a sufficient amount of an organic solvent followed by

dispersion into a suitable water soluble carrier. Suitable organic solvents include pharmaceutically acceptable solvents such as methanol, ethanol, or other organic solvents in which the protease inhibitor is soluble.

5    Suitable water soluble carriers include polymers such as polyethylene glycol (PEG), pluronics, pentaerythritol, pentaerythritol tetraacetate, polyoxyethylene stearates, poly- $\epsilon$ -caprolactone, and the like.

10    The organic solvent (preferably ethanol) may then be evaporated away, leaving the drug dispersed/dissolved in the molten matrix, which is then cooled. The solid matrix has the compound finely dispersed (molecular dispersion) in such a way that dissolution of the drug is maximized, thus improving the bioavailability of a drug exhibiting

15    dissolution rate limited absorption. Ease of manufacturing is also an attribute to this type of formulation. Once the organic solvent is evaporated to yield a solid mass, the mass may be ground, sized, and optionally formulated into an appropriate delivery system. Thus, by improving the

20    dissolution of a poorly water soluble drug, the drug in a suitable carrier may be filled into a gelatin capsule as a solid, or the matrix may potentially be compressed into a tablet.

The delivery system of the present invention results in increased solubility and bioavailability, and improved dissolution rate of the HIV protease inhibiting compound.

Other pharmaceutically-acceptable excipients may be added to the formulation prior to forming the desired final product. Suitable excipients include lactose, starch, magnesium stearate, or other pharmaceutically-acceptable fillers, diluents, lubricants, disintegrants, and the like, that might be needed to prepare a capsule or tablet.


The resulting composition comprising the pharmaceutical compound may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into capsules, or made into tablets for oral administration, or delivered by some other means obvious to those skilled in the art. The composition can be used to improve the oral bioavailability and solubility of said HIV protease inhibiting compound.

Total daily dosing of the pharmaceutical compound may be administered to a human in single or divided doses in amounts, for example, from 0.001 to 1000 mg/kg body weight daily, but more usually 0.1 to 50 mg/kg body weight daily. Dosage unit compositions may contain such amounts of

14

submultiples thereof to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, 5 time of administration, rate of excretion, drugs administered in combination and the severity of the particular disease undergoing therapy.

One type of pharmaceutical compound that may be employed in the practice of the present invention is an HIV 10 protease inhibitor. An example of an HIV protease inhibitor is ABT-538 (ritonavir), the chemical structure of which is represented hereinbelow as a compound of formula I



15


A compound of formula I is an HIV protease inhibitor marketed by Abbott Laboratories under the tradename Norvir<sup>®</sup>, with the common name ritonavir [(2S,3S,5S)-5-(N-(N-(N-



15

methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-  
 L-valinyl)amino-2-(N-  
 ((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-  
 hydroxyhexane]. This and other compounds as well as  
 5 methods for preparing same are disclosed in U.S. Patent  
 Nos. 5,648,497 and 5,541,206, the disclosures of which  
 are herein incorporated by reference.

Additional HIV protease inhibitors which may be  
 formulated into a solid dispersion of the instant  
 10 invention include compounds of formula II



II

15

A compound of formula II is known as ABT-378  
((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-  
hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-  
butanoyl)amino-1,6-diphenylhexane). This and other  
5 compounds, as well as methods for preparing same, are  
identified in U.S. Patent No. 5,914,332, the disclosure  
of which is herein incorporated by reference.

10

Other types of pharmaceutical compounds which may be  
employed in the practice of the present invention include  
but are not limited to antibacterial agents, antifungal  
15 agents such as griseofulvin, chemotherapeutic agents,  
agents for treating hyperlipidemia such as fenofibrate,  
and the like.

20 The following Examples are provided to further  
illustrate the present invention.

**EXAMPLES****Equipment:**

5

**DSC**

DSC measurements were made using a Mettler DSC 30 unit. Samples (4-7mg) were sealed in standard 40  $\mu$ l aluminum crucibles with a single hole punched in the  
10 lids. An empty crucible of the same type was used as a reference.

**X-ray Powder Diffraction Analysis**

An X-ray powder diffraction (XPD) pattern was  
15 obtained with a Scintag<sup>®</sup> XDS 2000  $\theta/\theta$  diffraction system equipped with a 2 kW normal focus X-ray tube and a liquid nitrogen cooled germanium solid state detector.

**Isothermal Calorimetry (TAM)**

20 The recrystallization reactions of 30% ABT-538 in PEG or PEG:PVP (95:5) solid dispersions were monitored via isothermal calorimetry (Thermometric 2277 Calorimeter) at 40 °C. Since crystallization is an exothermic process, a positive power output indicates

18

crystallization. The magnitude of the power output at any time is proportional to the rate of crystallization. XPD was used to confirm crystallization.

## 5 HPLC

The potency values of all the dispersions as well as the dissolution sample concentrations were determined via HPLC.

10 The effect of PVP on the crystallization rate of the drug in each dispersion system (drug with polymer) was investigated with the appropriate experimental technique. The results of these studies are provided in Figures 1-15.

15

Three pharmaceuticals of different properties were employed to demonstrate the general applicability of the instant invention. These compounds are identified in Table 1 below:

Table 1  
Model Compounds

| Property/Compound   | ABT-538 | Fenofibrate | Griseofulvin |
|---------------------|---------|-------------|--------------|
| MW (g/mole)         | 720.96  | 360.84      | 352.77       |
| T <sub>m</sub> (°C) | 124     | 79          | 218.13       |
| T <sub>g</sub> (°C) | 45.8    | -21.7       | 91           |

Example 1  
Dispersion Preparations

**A. Ritonavir (ABT-538) Dispersion Preparation:**

The samples were prepared by dissolving ABT-538 in a small volume of 200 proof ethanol in a 250 ml round bottom flask. The flask was vortexed and then placed in a water bath maintained at 75 °C. The PEG 8000 was added to the hot alcohol solution with continual swirling until the PEG melted. The flask was then attached to a rotary evaporator, immersed in the water bath (75 °C) under vacuum for 15 minutes to remove the ethanol. After the majority of ethanol had evaporated, the flask was immersed in an ice

bath for 15 minutes. The contents of the flask were then vacuum dried at room temperature overnight to remove residual alcohol. The dispersion was removed from the flask, gently ground, and sized to 40-100 mesh size. The drug loads used for these dispersions were 10, 20 and 30% w/w.

**B. ABT-378 Dispersion Preparation:**

The solid dispersion of 30% ABT-538 in 95:5 PEG8000:PVP was prepared by dissolving the ABT-538 and PVP 17 PF in a small volume of 200 proof ethanol in a 250 ml round bottom flask. The remainder of the process was as described above. A 30% ABT-538 dispersion in 85:15 PEG8000:PVP was also prepared similarly as were dispersions of 10 or 20% PVP 17PF in PEG 8000 without drug.

**C. Fenofibrate Dispersion Preparation:**

**15% Fenofibrate in PEG 8000:**

Both fenofibrate and PEG 8000 were sized to 40-100 mesh prior to mixing with a spatula on weighing paper. The mixture was then added to a 25 ml beaker and heated to 85°C in a water bath until the all the material had

melted. The molten solution was then poured onto a chilled X-ray sample holder to rapidly solidify the solution. The solid sample was immediately used to monitor the crystallization rate via X-ray powder  
5 diffraction.

**15% Fenofibrate in 90:10 PEG 8000:PVP:**

Fenofibrate (40-100 mesh) was added to the 90:10 PEG 8000:PVP control dispersion (see above) which was also  
10 sized to 40-100 mesh and mixed with spatula on a piece of weighing paper. The mixture was then processed as described above for the 15% fenofibrate dispersion in PEG 8000.

**15 D. Griseofulvin Dispersion Preparation:**

**15% griseofulvin in PEG 8000:**

Both griseofulvin and PEG 8000 were sized to 40-100  
20 mesh prior to mixing on a weighing paper with a spatula. The sample was then added to an 4 ml stainless steel vessel which was sealed under a N<sub>2</sub> atmosphere. The vessel was then immersed into an oil bath maintained at 180°C. The sample was occasionally shaken to mix the molten  
25 contents. After 5 minutes the vessel was immersed into a

liquid N<sub>2</sub> bath for 30 minutes. The contents of the vessel were removed, gently ground and sized to 40-100 mesh.

**15% griseofulvin in 80:20 PEG 8000:PVP:**

5

This dispersion was prepared in a similar manner as describe above for the 15% griseofulvin in PEG 8000 dispersion using the 80:20 PEG8000:PVP control dispersion.

10

**E. Results:**

**ABT-538:**

Figure 1 shows the X-ray powder diffraction (XPD) pattern of ABT-538, processed PEG 8000, a physical  
15 mixture of the two components and the 30% solid dispersion. A similar plot is shown in Figure 2 with PVP incorporated into the matrix. It is apparent from these figures that ABT-538 is not crystalline within either matrix. Figure 3 shows the DSC thermograms of ABT-538,  
20 PEG8000, the 30% physical mixture and the dispersion. A similar plot is seen in Figure 4 for the PEG:PVP dispersion. The endotherm associated with drug melting can clearly be discerned from the other components. Thus, it is possible to follow the kinetics of ABT-538



crystallization via DSC measurements. Crystallization kinetics were determined by heating the samples to 85°C, holding them isothermally for predetermined times followed by heating through the melting transition temperature of ABT-538. The heats of fusion were determined and ratioed against the heat of fusion of the drug melting in the physical mixture, giving the fraction crystallized. The percent crystallized as a function of isothermal (85°C) hold time is shown in Figure 5. It is clear from this experiment that the presence of PVP within the matrix suppresses the crystallization rate of ABT-538.

The crystallization rate was also followed via the heat associated with crystallization of ABT-538 using a isothermal calorimetry. The shapes and magnitudes of the crystallization peaks in Figure 6 indicate that ABT-538 crystallizes more readily in the PEG matrix as compared to the PEG:PVP matrix. This stabilizing effect of PVP is also reflected in the times required for complete crystallization (time to reach baseline) which were <10 hours for PEG and >30 hours for PEG:PVP (95:5). These data support the previous DSC results.

An additional study was performed with a dispersion containing 15% PVP. The samples were held at 50°C (above

the  $T_g$  of ABT-538) and X-ray diffraction patterns were measured over time to monitor for the appearance of crystalline ABT-538. Figure 7 shows that in the presence of PVP, crystalline ABT-538 is not present after 5 272 hours, while in PEG8000 alone crystalline drug is detected at 233 hours (and before, data not shown).

**Fenofibrate:**

Figure 8 shows the XPD patterns of PEG 8000, 10 fenofibrate, a 15% physical mixture and the 15% fenofibrate solid dispersion. The figure illustrates that the fenofibrate is X-ray-amorphous within the matrix. A similar plot with the XPD patterns for the 15% fenofibrate dispersion in a 90:10 PEG 8000:PVP matrix is 15 presented in Figure 9. Again, the fenofibrate is amorphous. Upon storage at 25°C, the fenofibrate begins to crystallize in the PEG 8000 matrix within 1 hour (Figure 10). Additional crystallization follows upto 12 hours, when the experiment was terminated. In the 20 presence of PVP (Figure 11), the fenofibrate does not crystallize in the timeframe of the experiment. This clearly demonstrates the inhibitory effects of PVP on crystallization within the PEG 8000 matrix.

**Griseofulvin:**

Similar XPD patterns for the griseofulvin dispersion in PEG 8000 and 80:20 PEG 8000:PVP matrices are shown in Figures 12 and 13, respectively. In both instances, 5 amorphous griseofulvin is isolated within the respective matrices. The XPD rate of crystallization experiments show that after one hour at 25°C, griseofulvin begins to crystallize (Figure 14). However, in the presence of PVP (Figure 15), crystallization is not observed even after 10 15 hours under the same conditions. This again demonstrates the inhibitory effects of PVP amorphous drug crystallization within a PEG matrix.

15 **E. Conclusions:**

The data presented demonstrate that PVP incorporated within a hydrophilic matrix, such as PEG 8000, inhibits crystallization of drug molecules having varying physicochemical properties. Thus, the instant invention 20 has a broad application to development of viable solid dispersion formulations where the high energy amorphous (non-crystalline) form of a drug is desired.

Example 2Stability of Dispersion in Molten PEG 8000

The stability of the dispersion of ABT-538 in PEG  
5 8000 in the molten state at 70 °C was examined.  
Individual approximately 5 mg quantities of the  
dispersion (aged for 6 weeks at room temperature) were  
placed in 4 ml glass vials. These vials, with the  
exception of the initial time point, were placed in a  
10 70 °C oven which was sampled at pre-determined intervals,  
chilled in ice water and placed in the freezer until HPLC  
analysis. After all samples were collected, they were  
analyzed for ABT-538 content by HPLC. The HPLC system  
consisted of a Hitachi AS 4000 autosampler, SP 8800  
15 ternary pump, Applied Biosystems 783 detector, and PE  
Nelson Data acquisition system. Other chromatographic  
details included a Regis Little Champ 5 cm C-18 column, a  
mobile phase consisting of an aqueous solution of 0.1%  
trifluoroacetic acid in 10 mM aqueous tetramethyl  
20 ammonium perchlorate (TMAP)/acetonitrile/methanol  
(55/40/5). The flow rate was 1 ml/minute, the wavelength  
of detection was 205 nm, and the injection volume was 100  
μl. Standard curves of peak area of ABT-538 vs.

concentration in the range of interest were compared with experimentally obtained area counts.

5

Example 3Protocol For Oral Bioavailability Studies

Dogs (beagle dogs, mixed sexes, weighing 7-14 kg) are  
10 fasted overnight prior to dosing, but are permitted water  
*ad libitum*. Each dog receives a 100  $\mu$ g/kg subcutaneous  
dose of histamine approximately 30 minutes prior to dosing.  
Each dog receives a single solid dosage form corresponding  
to a 5 mg/kg dose of the drug. The dose is followed by  
15 approximately 10 milliliters of water. Blood samples are  
obtained from each animal prior to dosing and at 0.25, 0.5,  
1.0, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after drug  
administration. The plasma is separated from the red cells  
by centrifugation and frozen (- 30 °C) until analysis. The  
20 concentrations of parent drug is determined by reverse  
phase HPLC with low wavelength UV detection following  
liquid-liquid extraction of the plasma samples. The parent  
drug area under the curve is calculated by the trapezoidal  
method over the time course of the study. The absolute  
25 bioavailability of each test composition is calculated by  
comparing the area under the curve after oral dosing to

that obtained from a single intravenous dose. Each capsule or capsule composition is evaluated in a group containing at least six dogs. The values reported are averages for each group of dogs.

**WE CLAIM:**

1. A pharmaceutical composition comprising a solid dispersion of a pharmaceutical compound, a water soluble  
5 carrier, and a crystallization inhibitor selected from the group consisting of polyvinylpyrrolidone (PVP) and hydroxypropylcellulose (HPMC).

2. The composition of Claim 1 wherein said water  
10 soluble carrier is polyethylene glycol (PEG).

3. The composition of Claim 1 wherein said pharmaceutical compound is an HIV protease inhibitor dissolved in an organic solvent.

15

4. The composition of Claim 3 wherein said organic solvent is ethanol.

5. The composition of Claim 3 wherein said HIV  
20 protease inhibitor is 2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir).

6. The composition of Claim 3 wherein said HIV  
protease inhibitor is (2S, 3S, 5S)-2-(2,6-  
Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-  
pyrimid-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane  
5 (ABT-378).

7. The composition of Claim 3 wherein said HIV  
protease inhibitor is a combination of 2S,3S,5S)-5-(N-(N-  
((N-methyl-N-((2-isopropyl-4-  
10 thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-  
thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-  
hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6-  
Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-  
pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane  
15 (ABT-378).

8. The composition of Claim 2 wherein said solid  
dispersion is encapsulated in a hard gelatin capsule.

20 9. The composition of Claim 2 wherein said solid  
dispersion is compressed into a tablet.

10. The composition of Claim 1 further comprising an  
additive or a mixture of additives independently selected



from the group consisting of pharmaceutically acceptable surfactants and antioxidants.

11. The composition of Claim 1 wherein said  
5 pharmaceutical compound is fenofibrate.

12. The composition of Claim 1 wherein said  
pharmaceutical compound is griseofulvin.

10 13. A method of preparing a composition of Claim 1  
which comprises:

- a) dissolving a pharmaceutical compound inhibitor  
into an organic solvent to form a solution;
- b) adding a water soluble carrier to said  
15 solution to form a mixture;
- c) adding PVP to said mixture of step b);
- d) optionally flash evaporating said solvent;
- e) optionally drying the resulting residue  
remaining after evaporation;
- 20 f) optionally grinding and sieving the solid  
dispersion to obtain a resultant product.

14. The method of Claim 13 additionally comprising encapsulating the solid dispersion in a hard gelatin capsule.

15 15. The method of Claim 13 additionally comprising compressing said solid dispersion into a tablet.

16. The method of Claim 13 wherein said pharmaceutical compound is an HIV protease inhibitor.

10

17. The method of Claim 16 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6)-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]amino-1,6-diphenylhexane (ABT-378).

20

18. The method of Claim 13 wherein said solvent is ethanol.

19. The method of Claim 13 wherein said water soluble carrier is polyethylene glycol (PEG).

20. A method of treating an HIV infection comprising  
5 administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is an HIV protease inhibitor.

21. The method of Claim 20 wherein said HIV protease  
10 inhibitor is selected from the group consisting of  
(2S,3S,5S)-5-(N-(N-(N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S, 3S, 5S)-2-(2,6)-  
15 Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]amino-1,6-diphenylhexane (ABT-378).

22. A method of treating hyperlipidemia comprising  
20 administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is fenofibrate.

23. A method of treating a fungal infection comprising administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment, wherein said pharmaceutical compound is

5 griseofulvin.

1/15




FIG.1

SUBSTITUTE SHEET (RULE 26)

2/15




FIG.2

SUBSTITUTE SHEET (RULE 26)

3/15




FIG.3

4/15




FIG.4

SUBSTITUTE SHEET (RULE 26)



5/15




FIG.5

SUBSTITUTE SHEET (RULE 26)

6/15




FIG.6

SUBSTITUTE SHEET (RULE 26)

7/15




FIG.7

SUBSTITUTE SHEET (RULE 26)

8/15




FIG.8

SUBSTITUTE SHEET (RULE 26)

9/15




FIG.9

SUBSTITUTE SHEET (RULE 26)

10/15




FIG.10

SUBSTITUTE SHEET (RULE 26)

11/15




FIG.11

SUBSTITUTE SHEET (RULE 26)

12/15




FIG.12

SUBSTITUTE SHEET (RULE 26)



13/15




FIG.13

14/15




FIG.14

SUBSTITUTE SHEET (RULE 26)

15/15




FIG.15

SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31072

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K9/14 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| X          | B.J. AUNGST ET AL.: "Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses"<br>INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 156, no. 1, 1997, pages 79-88, XP001009732<br>Amsterdam (NL)<br>cited in the application<br>page 81, paragraph 2.2<br>page 84; table 2 | 1-4,8,20              |
| A          |   | 13                    |
| X          | US 4 769 236 A (PANOS ET AL.)<br>6 September 1988 (1988-09-06)<br>cited in the application<br>claim 1   | 1,2,4                 |
|            | ---<br>-/--   |                       |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

19 June 2001

Date of mailing of the international search report

05/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/31072

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.     |
|------------|--|---------------------------|
| X          | WO 90 06115 A (HENNING BERLIN GMBH CHEMIE-<br>UND PHARMAWERK) 14 June 1990 (1990-06-14)<br><br>page 3, line 3 -page 6, line 7<br>page 8; example 1<br>---- | 1,2,4,<br>13-15,<br>18,19 |
| X          | GB 2 053 681 A (YAMANOUCHI PHARMACEUTICAL<br>CO. LTD.) 11 February 1981 (1981-02-11)<br>page 3; example 3<br>----  | 1,2                       |
| X          | WO 96 23499 A (SHERMAN)<br>8 August 1996 (1996-08-08)<br>page 10; example 1<br>-----<br><br>.<br>.<br>.  | 1,2                       |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/31072

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| US 4769236                                | A | 06-09-1988          | FR 2525108 A               | 21-10-1983          |
|   |   |                     | AR 230183 A                | 01-03-1984          |
|   |   |                     | AT 389813 B                | 12-02-1990          |
|   |   |                     | AT 427282 A                | 15-07-1989          |
|   |   |                     | AU 555579 B                | 02-10-1986          |
|   |   |                     | AU 9043182 A               | 27-10-1983          |
|   |   |                     | BE 894942 A                | 09-05-1983          |
|   |   |                     | CA 1225029 A               | 04-08-1987          |
|   |   |                     | CH 655003 A                | 27-03-1986          |
|   |   |                     | DE 3241097 A               | 20-10-1983          |
|   |   |                     | ES 517444 D                | 16-05-1985          |
|   |   |                     | ES 8505249 A               | 01-09-1985          |
|   |   |                     | GB 2119784 A,B             | 23-11-1983          |
|   |   |                     | IE 54084 B                 | 07-06-1989          |
|   |   |                     | IT 1153099 B               | 14-01-1987          |
|   |   |                     | JP 1677967 C               | 13-07-1992          |
|   |   |                     | JP 3041444 B               | 24-06-1991          |
|   |   |                     | JP 58183615 A              | 26-10-1983          |
|   |   |                     | LU 84468 A                 | 13-06-1983          |
|   |   |                     | NL 8204461 A               | 16-11-1983          |
|   |   |                     | PT 75867 A,B               | 01-12-1982          |
|   |   |                     | SE 8206697 A               | 20-10-1983          |
|   |   |                     | US 4610875 A               | 09-09-1986          |
| WO 9006115                                | A | 14-06-1990          | DE 3839825 A               | 13-06-1990          |
|   |   |                     | AT 92321 T                 | 15-08-1993          |
|   |   |                     | DE 58905187 D              | 09-09-1993          |
|   |   |                     | EP 0445158 A               | 11-09-1991          |
|   |   |                     | ES 2058602 T               | 01-11-1994          |
|   |   |                     | JP 2965689 B               | 18-10-1999          |
|   |   |                     | JP 4502004 T               | 09-04-1992          |
|   |   |                     | US 5368864 A               | 29-11-1994          |
| GB 2053681                                | A | 11-02-1981          | JP 1272484 C               | 11-07-1985          |
|   |   |                     | JP 56133217 A              | 19-10-1981          |
|   |   |                     | JP 59048810 B              | 29-11-1984          |
|   |   |                     | JP 1591530 C               | 30-11-1990          |
|   |   |                     | JP 2009007 B               | 28-02-1990          |
|   |   |                     | JP 56049314 A              | 02-05-1981          |
|   |   |                     | CA 1146866 A               | 24-05-1983          |
|   |   |                     | CH 648484 A                | 29-03-1985          |
|   |   |                     | DE 3024858 A               | 22-01-1981          |
|   |   |                     | ES 493152 D                | 16-11-1981          |
|   |   |                     | ES 8200557 A               | 01-02-1982          |
|   |   |                     | ES 499854 D                | 01-06-1982          |
|   |   |                     | ES 8205125 A               | 16-09-1982          |
|   |   |                     | FR 2460667 A               | 30-01-1981          |
|   |   |                     | FR 2489146 A               | 05-03-1982          |
|   |   |                     | IT 1132169 B               | 25-06-1986          |
|   |   |                     | SE 448342 B                | 16-02-1987          |
|   |   |                     | SE 8004938 A               | 06-01-1981          |
|   |   |                     | US 4343789 A               | 10-08-1982          |
|   |   |                     | US 4404183 A               | 13-09-1983          |
|   |   |                     | US 4673564 A               | 16-06-1987          |
| WO 9623499                                | A | 08-08-1996          | NZ 270439 A                | 26-04-1996          |
|   |   |                     | AU 706699 B                | 24-06-1999          |
|   |   |                     | AU 4478496 A               | 21-08-1996          |

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
PCT/US 00/31072

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9623499 A                              |                     | CA 2212309 A               | 08-08-1996          |
|   |                     | EP 0809497 A               | 03-12-1997          |
|   |                     | US 6132772 A               | 17-10-2000          |
|   |                     | ZA 9600576 A               | 14-08-1996          |
| <hr/>                                     |                     |                            |                     |

**THIS PAGE BLANK (USPTO)**